Skeletal muscle ultrastructure and function in statin-tolerant individuals

Muscle and Nerve

Volumn 53, Issue 2, 2016, Pages 242-251

  Rengo, Jason L ^a   Callahan, Damien M ^a,b   Savage, Patrick D ^a   Ades, Philip A ^a,b   Toth, Michael J ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Myalgia; Myopathy; Skeletal muscle; Statin; Ultrastructure

Indexed keywords

ACTIN; ATORVASTATIN; CALCIUM ION; CREATINE KINASE; MEVINOLIN; MYOSIN; MYOSIN HEAVY CHAIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACTIN MYOSIN INTERACTION; AGED; ARTICLE; BODY COMPOSITION; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTENSOR MUSCLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MORPHOLOGY; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE MITOCHONDRION; MUSCLE TONE; MYOFILAMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKELETAL MUSCLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFECTS; INNERVATION; KNEE; METABOLISM; SKELETAL MUSCLE CELL; ULTRASTRUCTURE; VERY ELDERLY;

ACTINS; AGED; AGED, 80 AND OVER; BODY COMPOSITION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KNEE; MALE; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOSIN HEAVY CHAINS;

EID: 84956573214     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24722     Document Type: Article

References (69)

1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701.
3. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-987.
4. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-2134.
5. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-736.
6. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-1025.
7. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(Pt B):2889-2934.
8. Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care 2015;38(Suppl):S4.
9. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation 2013;127:96-103.
10. Auer J, Sinzinger H, Franklin B, Berent R. Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiol. Published online September 17, 2014. doi: 10.1177/2047487314550804
11. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-2590.
12. Henriksbo BD, Lau TC, Cavallari JF, Denou E, Chi W, Lally JS, et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 2014;63:3742-3747.
13. Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW. Severe hepatic injury associated with different statins in patients with chronic liver disease: A nationwide population-based cohort study. J Gastroenterol Hepatol 2015;30:155-162.
14. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-1182.
15. Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol 2011;111:1477-1483.
16. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, et al. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 2008;26:343-351.
17. Galtier F, Mura T, Raynaud de Mauverger E, Chevassus H, Farret A, Gagnol JP, et al. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol 2012;263:281-286.
18. Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013;62:709-714.
19. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525-528.
20. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403.
21. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005;314:1032-1041.
22. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
23. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-581.
24. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008;359:789-799.
25. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194-200.
26. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010;41:185-190.
27. Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52:198-207.
28. Callahan DM, Miller MS, Sweeny AP, Tourville TW, Slauterbeck JR, Savage PD, et al. Muscle disuse alters skeletal muscle contractile function at the molecular and cellular levels in older adult humans in a sex-specific manner. J Physiol 2014;592(Pt 20):4555-4573.
29. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007;116:2110-2118.
30. Fogelholm M. Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 2010;11:202-221.
31. Sieverdes JC, Sui X, Lee DC, Church TS, McClain A, Hand GA, et al. Physical activity, cardiorespiratory fitness and the incidence of type 2 diabetes in a prospective study of men. Br J Sports Med 2010;44:238-244.
32. El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011;44:877-881.
33. Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 2010;362:564-565.
34. Fuzi M, Palicz Z, Vincze J, Cseri J, Szombathy Z, Kovacs I, et al. Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats. J Muscle Res Cell Motil 2012;32:391-401.
35. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007;117:3940-3951.
36. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol 2010;21:324-328.
37. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012;40:188-194.
38. Toth MJ, Miller MS, VanBuren P, Bedrin NG, LeWinter MM, Ades PA, et al. Resistance training alters skeletal muscle structure and function in human heart failure: effects at the tissue, cellular and molecular levels. J Physiol 2012;590(Pt 5):1243-1259.
39. Toth MJ, Shaw AO, Miller MS, VanBuren P, LeWinter MM, Maughan DW, et al. Reduced knee extensor function in heart failure is not explained by inactivity. Int J Cardiol 2010;143:276-282.
40. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J, et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr 1990;52:214-218.
41. Toth MJ, Miller MS, Ward KA, Ades PA. Skeletal muscle mitochondrial density, gene expression, and enzyme activities in human heart failure: minimal effects of the disease and resistance training. J Appl Physiol 2012;112:1864-1874.
42. Miller MS, Vanburen P, Lewinter MM, Lecker SH, Selby DE, Palmer BM, et al. Mechanisms underlying skeletal muscle weakness in human heart failure: alterations in single fiber myosin protein content and function. Circ Heart Fail 2009;2:700-706.
43. Bua EA, McKiernan SH, Wanagat J, McKenzie D, Aiken JM. Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol 2002;92:2617-2624.
44. Miller MS, VanBuren P, LeWinter MM, Braddock JM, Ades PA, Maughan DW, et al. Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humans. J Physiol 2010;588(Pt 20):4039-4053.
45. Kawai M, Saeki Y, Zhao Y. Crossbridge scheme and the kinetic constants of elementary steps deduced from chemically skinned papillary and trabecular muscles of the ferret. Circ Res 1993;73:35-50.
46. Zhao Y, Kawai M. The effect of the lattice spacing change on cross-bridge kinetics in chemically skinned rabbit psoas muscle fibers. II. Elementary steps affected by the spacing change. Biophys J 1993;64:197-210.
47. Palmer BM, Suzuki T, Wang Y, Barnes WD, Miller MS, Maughan DW. Two-state model of acto-myosin attachment-detachment predicts C-process of sinusoidal analysis. Biophys J 2007;93:760-769.
48. Mulieri LA, Barnes W, Leavitt BJ, Ittleman FP, LeWinter MM, Alpert NR, et al. Alterations of myocardial dynamic stiffness implicating abnormal crossbridge function in human mitral regurgitation heart failure. Circ Res 2002;90:66-72.
49. Miller MS, Bedrin NG, Callahan DM, Previs MJ, Jennings ME Jr, Ades PA, et al. Age-related slowing of myosin actin cross-bridge kinetics is sex specific and predicts decrements in whole skeletal muscle performance in humans. J Appl Physiol 2013;115:1004-1014.
50. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010;74:818-826.
51. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
52. Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 2009;102:625-633.
53. Traustadottir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr) 2008;30:283-291.
54. Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie Sayer A. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. Age Ageing 2010;39:185-191.
55. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007;55:420-425.
56. Maden-Wilkinson TM, Degens H, Jones DA, McPhee JS. Comparison of MRI and DXA to measure muscle size and age-related atrophy in thigh muscles. J Musculoskelet Neuronal Interact 2013;13:320-328.
57. Ivy JL, Costill DL, Maxwell BD. Skeletal muscle determinants of maximum aerobic power in man. Eur J Appl Physiol Occup Physiol 1980;44:1-8.
58. Ivy JL, Withers RT, Brose G, Maxwell BD, Costill DL. Isokinetic contractile properties of the quadriceps with relation to fiber type. Eur J Appl Physiol Occup Physiol 1981;47:247-255.
59. Gur H, Gransberg L, vanDyke D, Knutsson E, Larsson L. Relationship between in vivo muscle force at different speeds of isokinetic movements and myosin isoform expression in men and women. Eur J Appl Physiol 2003;88:487-496.
60. Huang SH, Hsiao CD, Lin DS, Chow CY, Chang CJ, Liau I. Imaging of zebrafish in vivo with second-harmonic generation reveals shortened sarcomeres associated with myopathy induced by statin. PLoS One 2011;6:e24764.
61. Rengo JL, Savage PD, Toth MJ, Ades PA. Statin therapy does not attenuate exercise training response in cardiac rehabilitation. J Am Coll Cardiol 2014;63:2050-2051.
62. Ades PA, Savage PD, Brawner CA, Lyon CE, Ehrman JK, Bunn JY, et al. Aerobic capacity in patients entering cardiac rehabilitation. Circulation 2006;113:2706-2712.
63. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 2012;59:60-70.
64. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006;55:551-557.
65. Simsek Ozek N, Bal IB, Sara Y, Onur R, Severcan F. Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles. Biochim Biophys Acta 2014;1840:406-415.
66. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102.
67. Draeger A, Sanchez-Freire V, Monastyrskaya K, Hoppeler H, Mueller M, Breil F, et al. Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle. Am J Pathol 2010;177:291-299.
68. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33:246-257.
69. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther 2007;321:626-634.